Supporting Information

Refactoring the Embden-Meyerhof-Parnas pathway as a whole of portable GlucoBricks for implantation of glycolytic modules in Gram-negative bacteria

by

Alberto Sánchez-Pascuala, Víctor de Lorenzo, and Pablo I. Nikel

SUPPLEMENTARY METHODS

Construction of mutant bacterial strains. Bacterial strains used in this study are listed in *Table S1*. A Δ*glk* derivative of *Pseudomonas putida* KT2440 was constructed by using the procedure described by Martínez-García and de Lorenzo1, using the suicide pEMG vector (*Table S2*). Suitable oligonucleotides (*PP_1011*-TS1F and *PP_1011*-TS1R, and *PP_1011*-TS2F and *PP_1011*-TS2R, *Table S3*) were employed to amplify *ca*. 500-bp long flanking regions upstream and downstream of *glk* (*PP_1011*) by PCR using chromosomal DNA from strain KT2440 as the template. A 1-kbp amplification product (i.e., spanning the TS1-TS2 regions flanking *glk*) was obtained using the two 500-bp amplicons mentioned above as the template and the external oligonucleotides (i.e., *PP_1011*-TS1F and *PP_1011*-TS2R) by splicing-by-overlap extension (*SOEing*) PCR2,3. The TS1- TS2 DNA fragment was digested with *Eco*RI and *Bam*HI, cloned into the I-*Sce*I–bearing pEMG vector digested with the same enzymes (giving rise to plasmid pEMGΔ*glk*) and verified by enzyme restriction and Sanger DNA sequencing (Secugen SL, Madrid, Spain). The suicide pEMGΔ*glk* plasmid was transferred to *P. putida* KT2440 by electroporation. Kanamycin (Km)-resistant colonies (i.e., chromosomal co-integration events) were checked by colony PCR1. Successful co-integrates were transformed with plasmid pSW-I, which allows for the resolution of co-integration events by inducing the expression of the gene encoding the I-*Sce*I homing meganuclease from *Saccharomyces cerevisiae* with sodium 3-methylbenzonate at 15 mM. The resultant Km-sensitive colonies were checked by PCR to select for the correct deletion events. Plasmid pSW-I was finally cured by successive passages on LB medium⁴ without antibiotics. The removal of the plasmid was tested by plating the cells onto LB plates containing 500 μg ml⁻¹ ampicillin.

Preparation of bacterial cell-free extracts. All the enzyme activity determinations were carried out in cell-free extracts obtained from bacterial cells harvested during the mid-exponential phase of growth [i.e., corresponding to an optical density measured at 600 nm (OD600) of *ca*. 0.5] or, in some cases, after 24 h of culture. Cell-free extracts were prepared starting from 50 ml of culture broth and centrifuging it at 4,000 r.p.m. for 15 min at 4ºC. Cell were washed twice with 25 ml of pre-cooled 67 mM potassium phosphate buffer (pH = 7.1) at 4°C. The washed pellets were suspended in 1 ml of the same buffer and centrifuging in 2-ml Eppendorf tubes at 8,000 r.p.m. for 10 min at 4ºC. After carefully removing the supernatant, the cell wet weight was obtained for each pellet in order to calculate the volume of reagents needed for protein extraction using the Novagen BugBuster™ protocol (EMD Millipore Corp., Billerica, MA, USA). Pellets and cell-free extracts were kept on ice throughout the whole procedure. Bacterial lysis was achieved by using 5 ml of BugBuster™ Protein Extraction Reagent per gram of cell paste. Afterwards, 1 µl of Lysonase™ Bioprocessing Reagent was added per 1 ml of BugBuster™ Protein Extraction Reagent used for re-suspension of the cells. Bacteria were lysed by shaking for 20 min at room temperature in a Rotamax 120 orbital shaker (Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) at 150 r.p.m. The insoluble cell debris was removed by centrifugation at 13,000 r.p.m. for 20 min at 4ºC and the supernatants (i.e., cell-free extracts) were stored at –20ºC until use.

- *In vitro* **enzymatic assays.** The activity of three key glycolytic enzymes (Glk, Pfk, and GA3P dehydrogenase) was assessed *in vitro* at 30ºC when using cell-free extracts from *P*. *putida* or at 37ºC when using cell-free extracts from *P*. *aeruginosa* and *Escherichia coli*, the remaining activities were measured at 25ºC as indicated by Sigma-Aldrich Co. (St. Louis, MO, USA) in the corresponding enzymatic assay protocols. All the enzymes were assessed under the optimal reported conditions for pH, substrate, and cofactor concentration5-8.
- *In vitro* assays were conducted in Nunc™ MicroWell™ 96-well microplates (Thermo Fisher Scientific Inc., Waltham, MA, USA) in a SpectraMaxTM M2e multi-mode microplate reader (Molecular Devices LLC, Sunnyvale, CA, USA). All the specific enzyme activities are reported as nmol substrate converted min-1 mg of protein-1.
- The protein concentration in cell-free extracts was obtained using the Bradford⁹ Protein Assay (Bio-Rad Laboratories Inc., Hercules, CA, USA). All the accessory enzymes (with the exceptions indicated below) were from *Saccharomyces cerevisiae* and they were purchased from Sigma-Aldrich Co. An extinction coefficient (ϵ_{NADPH}) of 6.22 mM⁻¹ cm⁻¹, representing the difference between the extinction coefficients of NAD(P)H and NAD(P)+, was used throughout. The specific protocols used for the determinations are detailed below.
- **Glk.** *ATP–D-Hexose 6-phosphotransferase* or *hexokinase* (EC 2.7.1.1). The reaction mixture contained 67 μ of 120 mM Tris HCl buffer (pH = 8.2), 26 μ of 500 mM glucose, 8 μ of 250 mM MgCl₂, 53 μ of 36 mM ATP, 10 µl of 20 mM NADP+, 13 µl of glucose-6-*P* dehydrogenase (15 units ml-1), 18 µl of water, and 5 µl of cell-free extract (or an appropriate dilution in 67 mM potassium phosphate buffer, pH = 7.1). The increase in the absorbance at 340 nm (*A*340) was measured during the assay.
- **Pgi.** *Phosphoglucose isomerase* (EC 5.3.1.9). The reaction mixture contained 33.3 µl of 240 mM glycylglycine Buffer (pH = 7.1), 6.7 µl of 100 mM D-fructose-6-*P*, 6.7 µl of 20 mM NADP+, 6.7 µl of 100 mM MgCl2, 6.7 µl of glucose-6-*P* dehydrogenase (50 units ml-1), 133.2 µl of water, and 6.7 µl of cell-free extract (or an appropriate dilution in 67 mM potassium phosphate buffer, pH = 7.1). The increase in *A*³⁴⁰ was measured during the assay.
- **Pfk.** *6-Phosphofructokinase* (EC 2.7.1.11). The reaction mixture contained 20 µl of 1 M Tris·HCl buffer ($pH = 7.5$), 2 µl of 100 mM fructose-6-P, 8 µl of 250 mM MgCl₂, 4 µl of 100 mM NH₄Cl, 4 µl of 10 mM NADH, 6 μ l of 36 mM ATP, 4 μ l of fructose-1,6- P_2 aldolase (50 units ml⁻¹), 1.5 μ l of triosephosphate isomerase (500 units ml-1), 1.5 µl of glycerol-3-*P* dehydrogenase from rabbit muscle (170 units ml⁻¹), 144 µl of water, and 5 µl of cell-free extract (or an appropriate dilution in 67 mM potassium phosphate buffer, pH = 7.1). The decrease in *A*³⁴⁰ was measured during the assay.
- **Aldolase.** *Aldolase* (EC 4.1.2.13). The reaction mixture contained 17.3 µl of 1 M Tris·HCl buffer (pH = 7.4), 6.7 µl of 58 mM fructose-1,6-*P*2, 1.9 µl of 14 mM NADH, 6.7 µl of α-glycerophosphate dehydrogenase/triosephosphate isomerase from rabbit muscle (50 units ml-1 each), 165.4 µl of water, and 2 µl of cell-free extract (or an appropriate dilution in 67 mM potassium phosphate buffer, pH = 7.1). The decrease in *A*³⁴⁰ was measured during the assay.
- **Tpi.** *Triose phosphate isomerase* (EC 5.3.1.1). The reaction mixture contained 20 µl of 1 M triethanolamine buffer (pH = 7.9), 2 µl of 0.5 M EDTA, 4 µl of glycerol-3-*P* dehydrogenase from rabbit muscle (17 units ml-1), 2 µl of 40 mM D,L-glyceraldehyde-3-*P*, 2 µl of 14 mM NADH, 168 µl of water, and 2 µl of cell-free extract (or an appropriate dilution in 67 mM potassium phosphate buffer, pH = 7.1). The decrease in *A*³⁴⁰ was measured during the assay.

GA3P dehydrogenase. *Glyceraldehyde-3-P dehydrogenase* [EC 1.2.1.12 (NAD+ dependent)/EC 1.2.1.13 NADP⁺ dependent)]. The reaction mixture contained 20 μ of 1 M Tris HCl buffer (pH = 7.5), 5 µl of 250 mM D,L-glyceraldehyde-3-*P*, 40 µl of 50 mM cysteine·HCl, 20 µl of 150 mM NaH2AsO4, 34 µl of 120 mM NaF, 20 µl of 35 mM NAD⁺ or NADP⁺, 56 µl of water, and 5 µl of cell-free extract (or an appropriate dilution in 67 mM potassium phosphate buffer, pH = 7.1). The increase in *A*³⁴⁰ was measured during the assay.

Table S1. Bacterial strains used in this study.

Table S1 (cont.). Bacterial strains used in this study.

^a Antibiotic markers: *Ap*, ampicillin; *Cm*, chloramphenicol; *Ery*, erythromycin; *Gm*, gentamicin; *Km*, kanamycin; *Nal*, nalidixic acid; *Rif*, rifampicin; *Sm*, streptomycin; *Sp*, spectinomycin; and *Tc*, tetracycline.

^b Strain obtained from the *E*. *coli* Genetic Stock Center (Yale University, New Haven, CT, USA).

Table S2. Plasmids used in this study.

^a Antibiotic markers: *Ap*, ampicillin; *Cm*, chloramphenicol; *Km*, kanamycin; *Sm*, streptomycin; and *Sp*, spectinomycin. Ts, temperature-sensitive origin of replication.

^b This plasmid is the same as pSW(I-*Sce*I)22, renamed here as pSW-I for simplicity.

Table S3. Oligonucleotides used in this study.

^a Bold letters indicate recognition site for the restriction enzymes and the complementary sequences used in splicing-by-overlap extension (*SOEing*2,3) PCR amplifications are shown in italics.

^b A PCR amplification using these oligonucleotides yields a 1,015-bp amplicon in the junction of the *pfkA* and *fbaA* genes.

^c A PCR amplification using these oligonucleotides yields a 938-bp amplicon in the junction of the *gpmA* and *eno* genes.

^d A PCR amplification using these oligonucleotides yields a 1,017-bp amplicon in the junction of the *phaC1* and *phaA* genes.

REFERENCES

- (1) Martínez-García, E., and de Lorenzo, V. (2011) Engineering multiple genomic deletions in Gramnegative bacteria: analysis of the multi-resistant antibiotic profile of *Pseudomonas putida* KT2440, *Environ. Microbiol. 13*, 2702-2716.
- (2) Nikel, P. I., and de Lorenzo, V. (2013) Implantation of unmarked regulatory and metabolic modules in Gram-negative bacteria with specialised mini-transposon delivery vectors, *J. Biotechnol. 163*, 143-154.
- (3) Horton, R. M. (1995) PCR-mediated recombination and mutagenesis: *SOEing* together tailormade genes, *Mol. Biotechnol. 3*, 93-99.
- (4) Green, M. R., and Sambrook, J. (2012) *Molecular cloning: a laboratory manual*, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- (5) Nikel, P. I., Chavarría, M., Fuhrer, T., Sauer, U., and de Lorenzo, V. (2015) *Pseudomonas putida* KT2440 strain metabolizes glucose through a cycle formed by enzymes of the Entner-Doudoroff, Embden-Meyerhof-Parnas, and pentose phosphate pathways, *J. Biol. Chem. 290*, 25920-25932.
- (6) Nikel, P. I., Kim, J., and de Lorenzo, V. (2014) Metabolic and regulatory rearrangements underlying glycerol metabolism in *Pseudomonas putida* KT2440, *Environ. Microbiol. 16*, 239- 254.
- (7) Chavarría, M., Nikel, P. I., Pérez-Pantoja, D., and de Lorenzo, V. (2013) The Entner-Doudoroff pathway empowers *Pseudomonas putida* KT2440 with a high tolerance to oxidative stress, *Environ. Microbiol. 15*, 1772-1785.
- (8) Nikel, P. I., and Chavarría, M. (2016) Quantitative physiology approaches to understand and optimize reducing power availability in environmental bacteria, In *Hydrocarbon and Lipid Microbiology Protocols–Synthetic and Systems Biology - Tools* (McGenity, T. J., Timmis, K. N., and Nogales-Fernández, B., Eds.), pp 39-70, Humana Press, Heidelberg, Germany.
- (9) Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, *Anal. Biochem. 72*, 248-254.
- (10) Manoil, C., and Beckwith, J. (1985) Tn*phoA*: a transposon probe for protein export signals, *Proc. Natl. Acad. Sci. USA 82*, 8129-8133.
- (11) Hanahan, D., and Meselson, M. (1983) Plasmid screening at high colony density, *Methods Enzymol. 100*, 333-342.
- (12) Datsenko, K. A., and Wanner, B. L. (2000) One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products, *Proc. Natl. Acad. Sci. USA 97*, 6640-6645.
- (13) Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, K. A., Tomita, M., Wanner, B. L., and Mori, H. (2006) Construction of *Escherichia coli* K-12 in-frame, singlegene knockout mutants: the Keio collection, *Mol. Syst. Biol. 2*, 2006.0008.
- (14) Jensen, K. F. (1993) The *Escherichia coli* K-12 "wild types" W3110 and MG1655 have an *rph* frameshift mutation that leads to pyrimidine starvation due to low *pyrE* expression levels, *J. Bacteriol. 175*, 3401-3407.
- (15) Bachmann, B. J. (1972) Pedigrees of some mutant strains of *Escherichia coli* K-12, *Bacteriol. Rev. 36*, 525-557.
- (16) Seta, F. D., Boschi-Muller, S., Vignais, M. L., and Branlant, G. (1997) Characterization of *Escherichia coli* strains with *gapA* and *gapB* genes deleted, *J. Bacteriol. 179*, 5218-5221.
- (17) Thomson, J., Gerstenberger, P. D., Goldberg, D. E., Gociar, E., Orozco de Silva, A., and Fraenkel, D. G. (1979) ColE1 hybrid plasmids for *Escherichia coli* genes of glycolysis and the hexose monophosphate shunt, *J. Bacteriol. 137*, 502-506.
- (18) Worsey, M. J., and Williams, P. A. (1975) Metabolism of toluene and xylenes by *Pseudomonas putida* (*arvilla*) mt-2: evidence for a new function of the TOL plasmid, *J. Bacteriol. 124*, 7-13.
- (19) Bagdasarian, M., Lurz, R., Rückert, B., Franklin, F. C. H., Bagdasarian, M. M., Frey, J., and Timmis, K. N. (1981) Specific purpose plasmid cloning vectors. II. Broad host range, high copy number, RSF1010-derived vectors, and a host-vector system for gene cloning in *Pseudomonas*, *Gene 16*, 237-247.
- (20) Stover, C. K., Pham, X. Q., Erwin, A. L., Mizoguchi, S. D., Warrener, P., Hickey, M. J., Brinkman, F. S. L., Hufnagle, W. O., Kowalik, D. J., Lagrou, M., Garber, R. L., Goltry, L., Tolentino, E., Westbrock-Wadman, S., Yuan, Y., Brody, L. L., Coulter, S. N., Folger, K. R., Kas, A., Larbig, K., Lim, R., Smith, K., Spencer, D., Wong, G. K. S., Wu, Z., Paulsen, I. T., Reizer, J., Saier, M. H., Hancock, R. E. W., Lory, S., and Olson, M. V. (2000) Complete genome sequence of *Pseudomonas aeruginosa* PAO1, an opportunistic pathogen, *Nature 406*, 959-964.
- (21) Cherepanov, P. P., and Wackernagel, W. (1995) Gene disruption in *Escherichia coli*: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant, *Gene 158*, 9-14.
- (22) Wong, S. M., and Mekalanos, J. J. (2000) Genetic footprinting with *mariner*-based transposition in *Pseudomonas aeruginosa*, *Proc. Natl. Acad. Sci. USA 97*, 10191-10196.
- (23) Peoples, O. P., and Sinskey, A. J. (1989) Poly-β-hydroxybutyrate (PHB) biosynthesis in *Alcaligenes eutrophus* H16. Identification and characterization of the PHB polymerase gene (*phbC*), *J. Biol.Chem. 264*, 15298-15303.
- (24) Silva-Rocha, R., Martínez-García, E., Calles, B., Chavarría, M., Arce-Rodríguez, A., de las Heras, A., Páez-Espino, A. D., Durante-Rodríguez, G., Kim, J., Nikel, P. I., Platero, R., and de Lorenzo, V. (2013) The Standard European Vector Architecture (SEVA): a coherent platform for the analysis and deployment of complex prokaryotic phenotypes, *Nucleic Acids Res. 41*, D666-D675.